Holen Sie sich die Stockscreener-App
4.05
2.41%
-0.10
Handel nachbörslich:
4.01
-0.04
-0.99%
Schlusskurs vom Vortag:
$4.15
Offen:
$4.06
24-Stunden-Volumen:
1.65M
Relative Volume:
1.01
Marktkapitalisierung:
$361.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-13.06
EPS:
-0.31
Netto-Cashflow:
$-31.85M
1W Leistung:
-2.88%
1M Leistung:
+46.21%
6M Leistung:
+53.41%
1J Leistung:
+213.95%
1-Tages-Spanne:
$4.05
$4.39
1-Wochen-Bereich:
$4.01
$4.675
52-Wochen-Spanne:
$1.27
$4.675
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
4.05 | 361.93M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online
Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com
Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz
Trevi Therapeutics sets $50 million stock offering price - Investing.com
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering - PR Newswire
Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results - Stocks Telegraph
Institutional investors control 39% of Trevi Therapeutics, Inc. (NASDAQ:TRVI) and were rewarded last week after stock increased 38% - Simply Wall St
Trevi stock rockets on Haduvio study update - MSN
Trevi stock rockets on Haduvio study update (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics stock soars to 52-week high of $4.07 - Investing.com
Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis - MarketWatch
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? - Benzinga
Trevi Therapeutics, Inc. Announces Positive Outcome from Sample Size Re-Estimation Resulting in No Change to the Current Sample Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - Marketscreener.com
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - PR Newswire
Trevi Therapeutics' Phase 2b CORAL Trial Hits Key Milestone with Strong Interim Analysis - StockTitan
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - The Eastern Progress Online
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Participate in September Investor and Medical Conferences - The Eastern Progress Online
HC Wainwright Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat
HC Wainwright Predicts Lower Earnings for Trevi Therapeutics - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - The Eastern Progress Online
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - The Eastern Progress Online
D. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi stock tumbles 23% amid Haduvio study results - MSN
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth - Yahoo Finance
Trevi Therapeutics Reports Positive Results for Human-Abuse Potential of Oral Nalbuphine - MarketWatch
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - GuruFocus.com
Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Fina - GuruFocus.com
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - PR Newswire
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference – Company Announcement - Financial Times
Trevi Therapeutics to Participate in Upcoming April Events - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages - MarketBeat
How Do Things Look For Trevi Therapeutics Inc (NASDAQ: TRVI) In The Short-Term? - Stocks Register
Trevi Therapeutics Announces Proposed Public Offering - Quantisnow
Trevi Therapeutics to Participate in Upcoming September Events - Quantisnow
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Quantisnow
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - MarketBeat
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Option Exercise |
1.43 |
4,219 |
6,033 |
217,532 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Option Exercise |
1.43 |
1,840 |
2,631 |
215,153 |
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Sale |
3.03 |
4,219 |
12,784 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Sale |
3.04 |
1,840 |
5,587 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Option Exercise |
1.43 |
40,277 |
57,596 |
253,590 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Option Exercise |
1.43 |
10,981 |
15,703 |
224,294 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Option Exercise |
1.43 |
3,863 |
5,524 |
217,176 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Sale |
3.11 |
40,277 |
125,310 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Sale |
3.02 |
10,981 |
33,205 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Sale |
3.02 |
3,863 |
11,677 |
213,313 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):